Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Primary or genetic haemochromatosis is an inherited disease characterized by an inappropriate degree of iron absorption with accumulation of excessive amounts of tissue iron. Parenchymal iron accumulation results in the typical clinical features of the disease including hepatic cirrhosis, diabetes, testicular atrophy and skin pigmentation. The disease is inherited in an autosomal recessive manner. The gene for the disease has not been identified but is tightly linked to the A locus of the histocompatibility complex on chromosome 6. The approximate homozygote frequency in Caucasians is 0.3% with an equal sex ratio. Excessive body iron stores have been described in a number of other conditions, particularly alcoholic liver disease. There is increasing evidence that many of these individuals are in fact also suffering from genetic haemochromatosis. Diagnostic tests including serum iron, transferrin saturation, serum ferritin and liver iron concentration make it possible to detect sufferers of the disease. Screening relatives of affected individuals with these tests allows a diagnosis to be made before permanent tissue damage has occurred. Removal of excess iron stores by repeated phlebotomy is the primary treatment. If iron is removed before significant tissue damage has occurred, the complications and natural course of the disease will be prevented provided reaccumulation of iron does not occur. Excessive iron accumulation with resultant organ damage also occurs in anaemias associated with ineffective erythropoiesis and after excessive parenteral iron administration or repeated blood transfusions. Similar clinical features may be seen. Chelation therapy is the mainstay of treatment in these cases where long-term venesection is not possible.
 ...
PMID:The clinical manifestations of chronic iron overload. 266 Sep 35

This study reports changes in levels of ferritin, haemoglobin and transferrin in the bone marrow, liver and spleen as an attempt to determine the causes of testicular iron depletion. A single oral dose of di-n-butyl phthalate (DBP) to male rats caused a sloughing of the germ cells (at 6 h) prior to testicular atrophy. Before the sloughing it was observed that DBP induced decreases both in the iron levels in the blood, bone marrow and testis and in haemoglobin (Hb) levels in the blood, bone marrow and spleen. Decrease in transferrin (Tf) levels was observed in the liver. Significant increases in ferritin and haemosiderin (Hs) levels were observed in the spleen and in the liver and spleen, respectively. In vitro studies where mono-n-butyl phthalate (MBP) was incubated with liver homogenates, MBP caused both the decreases in Hb and Tf-bound iron levels and increases in Hs and Hs-iron levels. The present study proposes that the mechanism of testicular atrophy by DBP might be associated with both the iron release from Hb and/or Tf in the liver and spleen and the subsequent depletion of iron in the blood and testes.
 ...
PMID:Mechanism of testicular atrophy induced by di-n-butyl phthalate in rats. Part 5. Testicular iron depletion and levels of ferritin, haemoglobin and transferrin in the bone marrow, liver and spleen. 866 21